Coya Therapeutics (COYA) Free Cash Flow (2022 - 2026)
Coya Therapeutics (COYA) posted Free Cash Flow of -$6.2 million for Q1 2026, down 516.46% sequentially from -$1.0 million in Q4 2025, and down 119.52% YoY from $31.8 million in Q1 2025.
Coya Therapeutics (COYA) Free Cash Flow (2022 - 2026) Analysis & Trends
Coya Therapeutics has reported Free Cash Flow for 5 years, with the latest figure at -$6.2 million in Q1 2026.
- Quarterly Free Cash Flow fell 119.52% year-over-year to -$6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.1 million (up 7.49% YoY) and the FY2025 annual result came in at -$10.7 million, down 4.38% from the prior year.
- Free Cash Flow declined to -$6.2 million in Q1 2026 per COYA's latest filing, from -$1.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $2.1 million in Q1 2024 and troughed at -$6.2 million in Q1 2026.
- A 5-year average of -$2.7 million and a median of -$2.2 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow jumped 155.54% in 2024, then slumped 231.8% in 2025.
- Over 5 years, Free Cash Flow stood at -$2.2 million in 2022, then decreased by 0.81% to -$2.2 million in 2023, then fell by 7.53% to -$2.4 million in 2024, then surged by 58.21% to -$1.0 million in 2025, then sank by 516.46% to -$6.2 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$6.2 million, -$1.0 million, and -$1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - | -7.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.38 Mn |
| Jun 30, 2026 | -7.38 Mn |
| Mar 31, 2026 | -6.21 Mn |
| Mar 31, 2026 | -6.21 Mn |
| Dec 31, 2025 | -1.01 Mn |
| Dec 31, 2025 | -1.01 Mn |
| Sep 30, 2025 | -1.13 Mn |
| Sep 30, 2025 | -1.13 Mn |
| Jun 30, 2025 | -5.77 Mn |
| Jun 30, 2025 | -5.77 Mn |
| Mar 31, 2025 | -2.83 Mn |
| Mar 31, 2025 | -2.83 Mn |
| Dec 31, 2024 | -2.41 Mn |
| Dec 31, 2024 | -2.41 Mn |
| Sep 30, 2024 | -5.46 Mn |
| Sep 30, 2024 | -5.46 Mn |
| Jun 30, 2024 | -4.56 Mn |
| Jun 30, 2024 | -4.56 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Mar 31, 2024 | 2.15 Mn |